

Attorney Docket No.: **DEX-0113**
Inventors: **Yang et al.**
Serial No.: **09/700,770**
Filing Date: **January 16, 2001**
Page 2

In the Claims:

1. (amended) A method for diagnosing the presence of lung cancer in a patient comprising:

(a) measuring levels of Lung Specific Gene in a sample of cells, tissue or bodily fluid obtained from the patient; and

(b) comparing the measured levels of Lung Specific Gene in the patient with levels of Lung Specific Gene in a sample of cells, tissue or bodily fluid obtained from a control, wherein an increase in measured levels of Lung Specific Gene in the patient versus the Lung Specific Gene levels in the control is associated with the presence of lung cancer and wherein the Lung Specific Gene comprises SEQ ID NO: 2, 3, 4, 5, or 6.

*Sub
B1*

2. (amended) A method of diagnosing metastatic lung cancer in a patient comprising:

(a) measuring levels of Lung Specific Gene in a sample of cells, tissue, or bodily fluid obtained from the patient; and

(b) comparing the measured levels of Lung Specific Gene in the patient with levels of Lung Specific Gene in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in measured Lung Specific Gene levels in the patient versus the Lung Specific Gene levels in the control is associated

Attorney Docket No.: **DEX-0113**
Inventors: **Yang et al.**
Serial No.: **09/700,770**
Filing Date: **January 16, 2001**
Page 3

with a cancer which has metastasized and wherein the Lung Specific Gene comprises SEQ ID NO: 2, 3, 4, 5, or 6.

3. (amended) A method of staging lung cancer in a patient comprising:

(a) identifying a patient suffering from lung cancer;
(b) measuring levels of Lung Specific Gene in a sample of cells, tissue, or bodily fluid obtained from the patient; and
(c) comparing the measured levels of Lung Specific Gene in the patient with levels of Lung Specific Gene in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of Lung Specific Gene versus the levels of Lung Specific Gene in the control is associated with a cancer which is progressing and a decrease in the measured levels of Lung Specific Gene versus the levels of Lung Specific Gene in the control is associated with a cancer which is regressing or in remission and wherein the Lung Specific Gene comprises SEQ ID NO: 2, 3, 4, 5, or 6.

4. (amended) A method of monitoring lung cancer in a patient for the onset of metastasis comprising:

Attorney Docket No.: **DEX-0113**
Inventors: **Yang et al.**
Serial No.: **09/700,770**
Filing Date: **January 16, 2001**
Page 4

(a) identifying a patient having lung cancer that is not known to have metastasized;

(b) measuring Lung Specific Gene levels in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of Lung Specific Gene in the patient with levels of Lung Specific Gene in cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of Lung Specific Gene in the patient versus the levels of Lung Specific Gene in the control is associated with a cancer which has metastasized and wherein the Lung Specific Gene comprises SEQ ID NO: 2, 3, 4, 5, or 6.

*Sub
B1*

5. A method of monitoring changes in a stage of lung cancer in a patient comprising:

(a) identifying a patient having lung cancer;

(b) measuring levels of Lung Specific Gene in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of Lung Specific Gene in the patient with levels of Lung Specific Gene in a sample of the same cells, tissue, or bodily fluid of a control, wherein an increase in the measured levels of Lung Specific Gene versus levels of Lung Specific Gene in the control is associated with a